APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.
12 July 2011
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners
13 June 2011
APR Applied Pharma Research s.a. and Labtec GmbH announce Ondansetron Oral Dispersible Film (“ODF”) is now available for licensing in Europe and selected non European countries, after having received marketing authorization in most countries of Europe.
Thanks to its chemical characteristics Bio'n creates a microenvironment which is favorable for wound
healing,unfavorable to the pathogens growth.
Complete
Non confidential
Opportunity
Profile
Experimental evidences: > Antimicrobial activity demonstrated in vitro vs bacteria, fungi and viruses > Improvement of healing of both acute and chronic wounds demonstrated in a rabbit
pre-clinical model: Bio’n induces a rapid wound closure; the histological evaluation
shows a good effect of Bio’n on skin neo-angiogenesis and extra-cellular matrix deposition.
